Shellacked: That’s The Word
Insights - How else to describe equity markets this year? The S&P 500, DOW, and NASDAQ have all returned below their 50-day and 200-day moving averages in … Continue Reading
Read nowAuthor Archives: Editorial Staff
Stocks Start the New Year on the Wrong Foot
Insights - Biopharma stocks are starting the year off on absolutely the wrong foot (though so is everything else), and last night’s SEVEN secondary stock offerings didn’t help Wednesday's price action.
PremiumA Strong Week Turned Flat
Insights - The week started with a bang and ended on a sour note, with the S&P 500 giving up a 60-point rally over the course of … Continue Reading
Read now
Recent Bottom-Pickers in OIL Got an Early Lump of COAL Instead
Insights - Investors who tried to time a bottom in oil over the last few months got an early lump of coal in their stockings. U.S. and Brent crude both plunged to new lows this week, taking the markets along for the ride. And, next week the Federal Reserve meets to lay out their latest plans for short-term interest rates. While a hike this month is largely expected by market participants, it's the clip at which interest rates will rise over the next few years that has investors on edge.
Read now
Bewildered By Oncothyreon? You Weren’t Alone
Research - We’ve got interesting signs of efficacy, but it’s difficult to draw strong conclusions about ONT-380’s ability to improve on, in combination with, existing HER2-targeted therapies without a head-to-head trial.
PremiumFirst Hint of What’s to Come With Sarepta and BioMarin
Insights - The event of the week - some would argue the event of the year - was the release of FDA briefing documents related to BioMarin's (BMRN) drisapersen, which faces an FDA advisory committee meeting this coming Tuesday. The drug is up for approval in Duchenne Muscular Dystrophy next month, and the upcoming committee meeting is all about FDA getting input from outside experts on the risk/benefit of approving drisapersen for DMD patients amenable to treatment by exon 51 skipping, drisapersen's mechanism of action.
Read nowOur Weekly Healthcare Look-Back
Insights - The markets took a rapid turn lower this week, which should come as no surprise to those who’ve watched equities’ equally swift rally over the … Continue Reading
Read now